Solu Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Solu Therapeutics's estimated annual revenue is currently $5M per year.
- Solu Therapeutics's estimated revenue per employee is $190,769
- Solu Therapeutics's total funding is $70M.
Employee Data
- Solu Therapeutics has 26 Employees.
- Solu Therapeutics grew their employee count by 30% last year.
Solu Therapeutics's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Co-founder, Head Business Strategy | Reveal Email/Phone |
3 | Co-founder and Chief Technology Officer | Reveal Email/Phone |
4 | Chief Medical Officer | Reveal Email/Phone |
5 | Chief Business Officer | Reveal Email/Phone |
6 | Chief Medical Officer | Reveal Email/Phone |
7 | CFO | Reveal Email/Phone |
8 | Chief Scientific Officer | Reveal Email/Phone |
9 | Chief Business Officer | Reveal Email/Phone |
10 | VP, Head Biology | Reveal Email/Phone |
Solu Therapeutics Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $12.7M | 82 | -45% | $107.3M | N/A |
#2 | $0.2M | 1 | -50% | N/A | N/A |
#3 | $6.2M | 40 | 21% | N/A | N/A |
#4 | $42.2M | 218 | 4% | $165M | N/A |
#5 | $14.6M | 94 | -37% | $312.8M | N/A |
#6 | $0.3M | 2 | -67% | N/A | N/A |
#7 | $235M | 366 | -5% | $340.9M | N/A |
#8 | $56M | 289 | -7% | $7.6M | N/A |
#9 | $4.7M | 61 | 36% | N/A | N/A |
#10 | $2M | 13 | 8% | N/A | N/A |
What Is Solu Therapeutics?
Solu Therapeutics is a precision-medicine company developing therapeutics to eliminate cells that drive oncologic, inflammatory, and autoimmune diseases.
keywords:N/A$70M
Total Funding
26
Number of Employees
$5M
Revenue (est)
30%
Employee Growth %
N/A
Valuation
N/A
Accelerator
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.8M | 26 | -24% | $50M |
#2 | $2.6M | 26 | -33% | $37.7M |
#3 | $2.9M | 26 | 4% | N/A |
#4 | $6.4M | 26 | 0% | N/A |
#5 | $5.9M | 26 | 8% | N/A |
